ALVO OAKTREE ACQUISITION CORP II

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers    

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers    

Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by Alvotech S.A. reached 6.73%, crossing above the 5% threshold of the total number of voting rights. The above percentage has been calculated on the basis of 22,484,087 own shares out of 334,038,147 shares in issue to which voting rights are attached.



EN
03/07/2025

Underlying

ALVOOAKTREE ACQUISITION CORP II

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Notification for the purposes of article 13 of the Luxembourg law of 1...

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers     Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by Alvotech S.A. reached 6.73%, crossing above the 5% threshold of the total number of voting rights. The above percentage has been calculated on the basis of 22,484,087 own shares out of 334,038,147 shares in issue to which voting rights are attached.

11h / 19m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Granting of Stock Options and Vesting of Restricted Share Units

Granting of Stock Options and Vesting of Restricted Share Units In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares. The aim of the stock option grants is to align the long-term interests of the board members and the Company. The relevant key terms and conditions of the Company´s Equity Incentive Plan approved by Alvotech’s Annua...

July 1, 2025 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Úthlutun nýrra kauprétta og afhending áunninna hlutabréfaréttinda

Úthlutun nýrra kauprétta og afhending áunninna hlutabréfaréttinda Í samræmi við starfskjarastefnu sem samþykkt var á aðalfundi Alvotech þann 6. júní 2023 og þar sem nýtt starfsár stjórnar hefst með aðalfundi, voru á aðalfundi félagsins sem haldinn var 25. júní sl. veittir kaupréttir til fjögurra óháðra stjórnarmanna. Hver stjórnarmaður fékk rétt til kaupa á alls 24.784 hlutum í Alvotech. Kaupréttarsamningunum er ætlað að samtvinna hagsmuni stjórnarmanna og Alvotech til lengri tíma. Skilmálar samninganna eru í samræmi við kaupréttarkerfi félagsins sem staðfest var á aðalfundi 13. júní 2022...

July 1, 2025 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech and Advanz Pharma Enter into European Supply and Commercializ...

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) REYKJAVIK, ICELAND and LONDON, UK (July 1, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commer...

July 1, 2025 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech and Advanz Pharma Enter into European Supply and Commercializ...

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a ...

July 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch